Rosacea in Gender-Affirming Care

Clinical Review · CR-002

1. Why rosacea is different here

Rosacea is a chronic, relapsing inflammatory condition of central facial skin, producing flushing, persistent redness, visible vessels, and — depending on phenotype — inflammatory papules and pustules, eye involvement, or skin thickening. Its pathophysiology is multifactorial and incompletely understood, involving neurovascular dysregulation, innate-immune and barrier changes (the cathelicidin/LL-37 pathway, mast cells), Demodex interactions and external triggers. Crucially, and unlike acne, it is not primarily androgen-driven. That reshapes the gender-affirming picture: where testosterone commonly and predictably increases acne risk, it has not been shown to drive rosacea; and where feminising therapy is a mixed story for acne, the limited observational evidence instead reports a lower recorded prevalence among transfeminine individuals receiving feminising hormone therapy — a finding that, as the next section shows, is far from straightforward.

2. Hormone therapy and rosacea — a genuinely contradictory picture

The trans finding. A single retrospective cohort study found that transfeminine people on feminising hormone therapy had a significantly lower recorded prevalence of rosacea than cisgender men, cisgender women, and trans people not on feminising therapy, and no significant association for masculinising therapy.^[1] A systematic review reports the same.^[2] Taken alone, that might suggest oestrogen or anti-androgens are favourable.

The cisgender evidence points the other way. This is where honesty matters. Larger cisgender observational analyses associate exogenous oestrogen with a higher recorded or incident risk of rosacea: in the Nurses’ Health Study II (US White health professionals, so of limited generalisability), incident rosacea rose with menopausal hormone therapy and oral contraceptives, and was lower after menopause;^[4] a UK Biobank analysis found similar positive associations for hormone-replacement therapy and oral contraceptives, paired with mouse and keratinocyte models in which 17β-oestradiol amplified rosacea-like inflammation through GPR30/GPER1 signalling.^[5] These are different populations, exposures and endpoints from the trans study, and not directly interchangeable with gender-affirming-hormone-therapy data — but they certainly do not support, and arguably run against, the idea that oestrogen protects against rosacea.

What to make of the conflict. Two observational literatures that are directionally discordant — but not directly comparable, differing in population, exposure, endpoint and design — do not average into a conclusion; they mark the limits of what is known. The most defensible reading is that the hormone–rosacea relationship is unresolved, and that the lower recorded prevalence in transfeminine people is as likely to reflect confounding as any true hormonal effect. People on feminising therapy are, by definition, engaged with healthcare and may be examined and diagnosed differently; detection and diagnostic bias, differing healthcare access, and age or socioeconomic differences between the compared groups are all plausible explanations a retrospective prevalence design cannot exclude, and no effect sizes or confidence intervals from the trans study are reproduced here to imply precision. Sex-hormone biology in rosacea is incompletely understood and not a matter of consensus. The practical consequence is simple: rosacea should not be expected to respond predictably to hormonal change, in either direction.

3. The diagnostic trap: flushing that is not rosacea

The most useful clinical point in this review is a diagnostic one. Changes in sex-steroid signalling on feminising therapy — hypogonadal or fluctuating sex-steroid states, oestrogen dose changes, the use of GnRH analogues, and menopause-like states — can produce vasomotor flushing and hot flushes that resemble the flushing of rosacea. The two are not the same. Hormone-related flushing is a systemic vasomotor phenomenon reflecting broader endocrine change; rosacea flushing is one feature of a facial condition that is both neurovascular and inflammatory, and comes with other signs (persistent central erythema, telangiectasia, papulopustules, ocular symptoms). Systemic features — sweating, palpitations, a generalised sensation of heat, sleep disturbance, or timing that tracks hormone changes — point towards vasomotor flushing rather than rosacea. Mistaking one for the other leads to the wrong treatment — rosacea therapies do not address the endocrine driver of hormonal flushing, and hormonal explanations will not address true rosacea. Where both coexist, each is addressed on its own terms. Persistent, disabling vasomotor flushing that is not rosacea sometimes prompts specialist use of agents such as beta-blockers, clonidine, certain antidepressants (SSRIs/SNRIs), gabapentin, oxybutynin or, where available, neurokinin-3 receptor antagonists — jurisdiction-dependent, and a decision for the treating clinician, not a rosacea treatment.

4. Assessment

Diagnosis is clinical and phenotype-led, following the ROSCO approach of classifying by presenting features rather than rigid subtypes: flushing/transient erythema, persistent central erythema, telangiectasia, inflammatory papules and pustules (without comedones, which point to acne), phymatous change, and ocular features.^[3] Less common variants — granulomatous rosacea and persistent facial lymphoedema (Morbihan disease) — are worth recognising, as they behave and respond differently.

Consider a broad differential. Not every central facial redness is rosacea. Consider hormone-related vasomotor flushing (above), seborrhoeic and perioral dermatitis, acne, steroid-induced rosacea, demodicosis, contact and photodermatitis, and — where the pattern is atypical — connective-tissue disease (lupus, dermatomyositis) and the rarer systemic causes of flushing (carcinoid, mast cell disorders).

Skin of colour. Rosacea is under-recognised in darker skin, where erythema and telangiectasia are harder to see against the background tone and the condition is more often identified late or missed; post-inflammatory pigment alteration is also more consequential.^[7] Active inspection (for warmth, papules, ocular signs), asking about symptoms rather than relying on visible erythema — burning, stinging and episodic warmth — a lower diagnostic threshold, and dermoscopy (which can reveal vascular patterns not visible to the naked eye) all help close that gap.

Triggers. Ask about the common provocations — ultraviolet and heat, sun, alcohol, spicy food, hot drinks, exercise and emotional stress — since identifying and moderating a person’s own triggers does much of the work of control.

5. Management

Management follows standard, phenotype-directed rosacea principles, and starts from the premise that rosacea is chronic and relapsing: treatment controls features and needs maintenance rather than curing the condition.^[3]

Foundations for everyone. Gentle, non-stripping skincare, a barrier-supporting moisturiser, and daily broad-spectrum sunscreen (ultraviolet is among the most consistent aggravators), plus working through individual triggers. Barrier care means avoiding harsh exfoliation — physical scrubs and high-strength acid peels — and alcohol-containing or fragranced products; it does not mean avoiding every active, and some acids used carefully (for example azelaic acid) are themselves rosacea treatments.

Erythema and flushing are distinct treatment targets from papules. Topical brimonidine or oxymetazoline can transiently reduce background redness, but patients should be warned about rebound erythema and occasional paradoxical worsening, well recognised with brimonidine, which can leave skin redder as the effect wears off.

Papules and pustules. Topical agents first — azelaic acid, ivermectin (which also targets Demodex) or metronidazole — stepping up to oral therapy for more inflammatory disease, typically sub-antimicrobial-dose doxycycline, used for its anti-inflammatory rather than antibacterial effect (supporting antibiotic stewardship).^[3]

Persistent vessels and phyma. For fixed telangiectasia and background erythema, energy-based devices — vascular lasers (pulsed-dye, KTP) and intense pulsed light for finer superficial vessels and diffuse erythema, with long-pulsed Nd:YAG generally reserved for deeper or larger-calibre vessels — are among the most effective options for persistent vascular features, since topical and oral therapy do little for established vessels.^[6] They are not equivalent to one another; device choice depends on vessel calibre, depth and skin phototype; response varies, several sessions are usual, and recurrence is common, so maintenance is often needed.^[6] Early phymatous change may respond to low-dose isotretinoin, but the evidence is stronger for refractory papulopustular disease than for phyma, and established phymatous rosacea (such as rhinophyma) usually needs physical or laser reduction rather than medication.

Ocular rosacea is easy to under-treat. It is managed with lid hygiene (warm compresses, lid-margin cleansing), ocular lubricants, and systemic doxycycline where indicated — with ophthalmology referral for anything beyond mild disease, or for pain, visual change or corneal involvement.

Isotretinoin, doxycycline and pregnancy. Both oral options matter for anyone who could become pregnant, including some trans men who retain fertility: isotretinoin is severely teratogenic (with the pregnancy-prevention-programme considerations set out in the acne review), and tetracyclines including doxycycline are avoided in pregnancy. Reproductive potential, not gender identity, drives these precautions.

And not by changing hormones. Because the hormonal evidence is contradictory and no protective or harmful effect is established, rosacea is not a reason to alter gender-affirming hormones. It is treated directly, on its own merits.

6. The energy-device interface

There is a practical crossover worth naming carefully. Many trans people are already attending laser and light services for hair removal, so a pathway to energy-based treatment is often already open. But the treatments are not interchangeable: hair-removal devices target pigment in the follicle and use different wavelengths, settings and endpoints from the vascular lasers and intense pulsed light used for rosacea’s redness (and intense pulsed light is not, strictly, a laser). Rosacea-prone, easily-flushed, often barrier-impaired skin needs a cautious, appropriately-tuned approach: phototype- and target-adjusted parameters, avoiding treatment during an active flare, and care around recent isotretinoin (a traditional caution now debated but still commonly observed) and recent tanning. In darker skin phototypes the risk of post-treatment dyspigmentation is higher, which shapes device choice and settings and makes test spots advisable before a full treatment. Coordinating any rosacea light treatment with a person’s wider hair-removal plan (see the hair-removal reviews) is sensible, but it should be delivered as vascular treatment by an appropriately trained practitioner, not folded into a hair-removal appointment.

7. Evidence quality

The trans-specific evidence is thin and, read alongside the cisgender literature, internally contradictory. The trans finding rests on a single retrospective prevalence study with no independent replication;^[1] the larger cisgender cohorts associate oestrogen with the opposite direction of effect.^[4,5] Prevalence is not incidence or severity; the trans design cannot exclude detection bias, diagnostic differences or confounding; and no effect sizes are reproduced here to imply precision. The honest position is that no causal or protective conclusion about hormones and rosacea is warranted in either direction, and there are no trans-specific treatment trials. The management guidance, by contrast, is well-established phenotype-led rosacea dermatology;^[3] the topical and oral evidence is robust, though device and light studies remain heterogeneous and their efficacy estimates less certain.^[6]

Clinical bottom line

1. The hormone–rosacea relationship is genuinely unresolved — a single trans prevalence study suggesting less rosacea on feminising therapy sits against larger cisgender data linking oestrogen to more — so rosacea is not a reason to alter gender-affirming hormones, and should not be expected to respond to hormonal change.^[1,4]
2. Separate true rosacea from hormone-related flushing before treating; they need different approaches.
3. Treat by phenotype with standard care — barrier, photoprotection, topicals, orals, ocular management — and use energy-based devices for persistent redness, expecting variable response and recurrence.^[3,6]
4. Look for rosacea actively in darker skin, where it is easily missed and pigment change matters more.^[7]